Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Supercomputers Used to Create Synthetic, Germ-Fighting Compounds

By LabMedica International staff writers
Posted on 16 Apr 2009
Since studies indicate that bacteria have little or no ability to resist antimicrobial peptides, one of the most fascinating possibilities of this finding is the creation of new forms of antibiotics to fight bacteria that have become resistant or immune to conventional drugs. More...
Scientists are now utilizing supercomputers to design and create synthetic small organic molecules and polymers--easier to make than peptides--that have the same mechanism of action as host defense proteins and with similar germ-fighting ability.

Based on the success of this research, scientists from the University of Pennsylvania (Philadelphia, PA, USA) filed for several patents and spun off of a biotech company named PolyMedix, Inc. (Radnor, PA, USA) to investigate the possibilities for useful applications as both novel therapeutic antibiotic drugs and as antimicrobial polymers for biomaterials applications.

These investigational antibiotic agents are the first of their kind to directly address the serious medical problem of bacterial drug resistance. The host defense proteins work essentially differently from all other known antibiotics: they punch holes directly in bacterial cell membranes, via a biophysical instead of a biochemical mechanism of action, in ways that makes resistance unlikely to develop. Up to now, data from a phase I study demonstrate that the compound is safe, and well-tolerated single doses were achieved at levels suggesting a beneficial therapeutic index. Additional clinical development will continue for the initial indication for this drug as a treatment for pan-Staphylococcal infections.

Staphylococcus aureus colonizes, without infecting, up to 30% of the human population. With the superbug's ubiquity and ability to invade almost any environment, no place is considered a safe haven against this deadly bacteria. Drug-resistant bacterial infections are one of the most significant medical problems facing the global population. Once typically thought of as a cure-all, antibiotics were the initial line of defense. Unfortunately, bacteria are becoming resistant to antibiotics due to overuse. While antibiotics-resistant superbugs are indeed a terrifying medical development, these newer innovative therapies suggest they are not invulnerable.

Related Links:

University of Pennsylvania
PolyMedix



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.